Encompass Health (EHC) Expected to Release Earnings on Wednesday

Key Points

• Q3 2026 earnings are expected Wednesday, October 28, after the market closes. Analysts project $1.36 in EPS and $1.60 billion in revenue; the earnings call is scheduled for October 29.
• Encompass Health’s previous quarter exceeded expectations, with $1.55 EPS and $1.60 billion in revenue, while revenue increased 9.6% year over year.
• The company raised its quarterly dividend to $0.21 from $0.19, and analysts maintain a consensus “Buy” rating with an average price target of $148.50.

Encompass Health (NYSE:EHC - Get Free Report) is anticipated to post its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect Encompass Health to announce earnings of $1.36 per share and revenue of $1.60 billion for the quarter. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Individuals may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 10:00 AM ET.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share for the quarter, topping analysts' consensus estimates of $1.48 by $0.07. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. Encompass Health had a return on equity of 18.08% and a net margin of 10.01%. The firm's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.40 earnings per share. On average, analysts expect Encompass Health to post $6.08 EPS for the current fiscal year and $6.60 EPS for the next fiscal year.

Encompass Health Stock Performance

Shares of NYSE EHC opened at $121.59 on Wednesday. Encompass Health has a 1 year low of $92.77 and a 1 year high of $129.96. The firm has a market cap of $11.99 billion, a P/E ratio of 19.80, a PEG ratio of 2.46 and a beta of 0.74. The stock has a fifty day moving average price of $122.37 and a two-hundred day moving average price of $112.01. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.19 and a current ratio of 1.19.

Encompass Health Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st were paid a $0.21 dividend. The ex-dividend date of this dividend was Thursday, October 1st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Encompass Health's previous quarterly dividend of $0.19. Encompass Health's dividend payout ratio (DPR) is presently 13.68%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on EHC. Wall Street Zen lowered Encompass Health from a "buy" rating to a "hold" rating in a report on Saturday. Weiss Ratings raised Encompass Health from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. TD Cowen lifted their target price on Encompass Health from $125.00 to $140.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Barclays boosted their price target on shares of Encompass Health from $140.00 to $144.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Finally, UBS Group upped their price target on shares of Encompass Health from $150.00 to $155.00 and gave the company a "buy" rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $148.50.

Insider Buying and Selling

In other Encompass Health news, CEO Mark J. Tarr sold 173,148 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.47, for a total value of $21,724,879.56. Following the transaction, the chief executive officer owned 267,814 shares of the company's stock, valued at approximately $33,602,622.58. This represents a 39.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP John Darby sold 4,858 shares of the stock in a transaction on Monday, August 31st. The shares were sold at an average price of $121.09, for a total value of $588,255.22. Following the sale, the executive vice president owned 75,041 shares of the company's stock, valued at $9,086,714.69. This trade represents a 6.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 186,912 shares of company stock valued at $23,434,845 over the last 90 days. 1.80% of the stock is currently owned by insiders.

Encompass Health Company Profile

Encompass Health Corporation NYSE: EHC is a healthcare services company that operates inpatient rehabilitation hospitals in the United States and Puerto Rico. Its hospitals provide intensive rehabilitation to patients recovering from conditions such as stroke, brain and spinal cord injuries, neurological disorders, amputations, hip fractures and other serious illnesses or injuries.

The company's services typically include nursing care, physical therapy, occupational therapy, speech and language therapy, respiratory therapy and medical management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.